KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EBITDA: 2009-2024

Historic EBITDA for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -$303.0 million.

  • Teva Pharmaceutical Industries' EBITDA rose 1829.41% to $882.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 279.05%. This contributed to the annual value of -$303.0 million for FY2024, which is 169.98% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported EBITDA of -$303.0 million as of FY2024, which was down 169.98% from $433.0 million recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' EBITDA registered a high of $1.7 billion during FY2021, and its lowest value of -$3.6 billion during FY2020.
  • Over the past 3 years, Teva Pharmaceutical Industries' median EBITDA value was -$303.0 million (recorded in 2024), while the average stood at -$689.0 million.
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 706.32% in 2020, then spiked by 148.04% in 2021.
  • Teva Pharmaceutical Industries' EBITDA (Yearly) stood at -$3.6 billion in 2020, then surged by 148.04% to $1.7 billion in 2021, then tumbled by 228.03% to -$2.2 billion in 2022, then surged by 119.71% to $433.0 million in 2023, then plummeted by 169.98% to -$303.0 million in 2024.